EUR-1025
Collaboration Partner:
Eurand
Indication:
Anti-emetic
Status:
Phase l
Profile:
EUR-1025 is a once-a-day oral formulation of ondansetron, an anti-emetic, or agent to prevent nausea and vomiting, sold under the brand name Zofran by GlaxoSmithKline. For the 12 months ended June 30, 2006, Zofran, which is currently administered two, three and four times per day, had worldwide sales of approximately $2.0 billion, approximately half of which were for the oral dosage form. The product is in formulation and clincal development. This product is being developed using our Diffucaps® technology.